PDS Biotechnology Overview
- Year Founded
-
2005
- Status
-
Public
- Employees
-
21
- Stock Symbol
-
PDSB
- Investments
-
1
- Share Price
-
$0.87
- (As of Friday Closing)
PDS Biotechnology General Information
Description
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
Contact Information
Website
www.pdsbiotech.comCorporate Office
- 303A College Road East
- Princeton, NJ 08540
- United States
Corporate Office
- 303A College Road East
- Princeton, NJ 08540
- United States
PDS Biotechnology Timeline
PDS Biotechnology Stock Performance
As of 13-Nov-2026, PDS Biotechnology’s stock price is $0.87. Its current market cap is $107M with 123M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.87 | $0.98 | $0.20 - $1.79 | $107M | 123M | 25.2M | -$0.54 |
PDS Biotechnology Financials Summary
As of 30-Sep-2026, PDS Biotechnology has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 53,174 | 33,893 | 35,895 | 123,959 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (31,522) | (36,300) | (43,028) | |
| Net Income | (32,283) | (34,496) | (37,610) | (42,942) |
| Total Assets | 18,572 | 30,494 | 45,359 | 59,390 |
| Total Debt | 0 | 16,926 | 21,828 | 23,852 |
PDS Biotechnology Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
PDS Biotechnology Comparisons
Industry
Financing
Details
PDS Biotechnology Competitors (67)
One of PDS Biotechnology’s 67 competitors is Arcus Biosciences, a Formerly VC-backed company based in Hayward, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Arcus Biosciences | Formerly VC-backed | Hayward, CA | ||||
| Aura Biosciences | Formerly VC-backed | Boston, MA | ||||
| BriaCell Therapeutics | Corporation | West Vancouver, Canada | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA |
PDS Biotechnology Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
PDS Biotechnology Patents
PDS Biotechnology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260265326-A1 | Il-12 fusion protein formulations and methods of use thereof | Pending | 07-May-2024 | ||
| WO-2025235559-A1 | Il-12 fusion protein formulations and methods of use thereof | Pending | 07-May-2024 | ||
| AU-2023365611-A1 | Recombinant protein compositions formulated with enantio-specific cationic lipids and uses thereof | Pending | 21-Oct-2022 | ||
| JP-2025536346-A | Recombinant protein compositions formulated with enantiospecific cationic lipids and uses thereof | Pending | 21-Oct-2022 | ||
| EP-4604997-A2 | Recombinant protein vaccines formulated with enantio-specific cationic lipid r-dotap and methods of use thereof | Pending | 21-Oct-2022 | A61K39/145 |
PDS Biotechnology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
PDS Biotechnology Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
PDS Biotechnology Acquisitions (1)
PDS Biotechnology’s most recent deal was a Merger/Acquisition with Edge Therapeutics for . The deal was made on 15-Mar-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Edge Therapeutics | 15-Mar-2019 | Merger/Acquisition | Drug Discovery |
PDS Biotechnology ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
38.8 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
PDS Biotechnology FAQs
-
When was PDS Biotechnology founded?
PDS Biotechnology was founded in 2005.
-
Where is PDS Biotechnology headquartered?
PDS Biotechnology is headquartered in Princeton, NJ.
-
What is the size of PDS Biotechnology?
PDS Biotechnology has 21 total employees.
-
What industry is PDS Biotechnology in?
PDS Biotechnology’s primary industry is Biotechnology.
-
Is PDS Biotechnology a private or public company?
PDS Biotechnology is a Public company.
-
What is PDS Biotechnology’s stock symbol?
The ticker symbol for PDS Biotechnology is PDSB.
-
What is the current stock price of PDS Biotechnology?
As of 13-Nov-2026 the stock price of PDS Biotechnology is $0.87.
-
What is the current market cap of PDS Biotechnology?
The current market capitalization of PDS Biotechnology is $107M.
-
Who are PDS Biotechnology’s competitors?
Arcus Biosciences, Aura Biosciences, BriaCell Therapeutics, Ayala Pharmaceuticals, and Sorrento Therapeutics are some of the 67 competitors of PDS Biotechnology.
-
What is PDS Biotechnology’s annual earnings per share (EPS)?
PDS Biotechnology’s EPS for 12 months was -$0.54.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
